European Commission approves first-line pembrolizumab for high PD-L1, EGFR/ALK- NSCLC

The European Commission has approved pembrolizumab, an anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression (tumour proportion score [TPS] of 50 percent or...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kQtNdY
via IFTTT